Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

October 05, 2023

Saad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.

September 29, 2023

Damon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.

September 29, 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

September 29, 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

September 27, 2023

Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.

September 24, 2023

Ezra Rosen, MD, PhD, highlights the early-phase investigation of zotatifin in estrogen receptor-positive metastatic breast cancer, explains the agent’s unique mechanism of action as well as its efficacy and safety in a heavily pretreated population, and underscores the need for improved sequencing of the myriad of treatment options in the post–CDK4/6 inhibitor space.

September 22, 2023

Saad Z. Usmani, MD, MBA, FACP, discusses unmet needs in patients with high-risk multiple myeloma being treated in the frontline setting, highlighting areas of potential further exploration within this landscape.

September 22, 2023

Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.

September 15, 2023

Saad Z. Usmani, MD, MBA, FACP, discusses methods for identifying patients with high-risk multiple myeloma and notable disease characteristics in this population.

September 10, 2023

Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy.

September 06, 2023

A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

September 04, 2023

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

September 01, 2023

Prioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.

August 28, 2023

Prioty Islam, MD, MSc, discusses the exploration of novel roles for BTK inhibitors in the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia.

August 22, 2023

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

August 22, 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

August 18, 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

August 18, 2023

Prioty Islam, MD, MSc, discusses how the FDA approval of the noncovalent BTK inhibitor pirtobrutinib has transformed the treatment of patients with mantle cell lymphoma, and where this agent fits in to the current treatment armamentarium.

August 17, 2023

Deb Schrag, MD, MPH, discusses the rationale for exploring the use of selective preoperative chemoradiation in patients with locally advanced rectal cancer, the safety and efficacy findings from the PROSPECT trial, and the importance of reviewing patient-reported outcomes during clinical trials.

August 15, 2023

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.